UNASSIGNED:嘴唇是一种独特的组织类型,充当口腔的“屏障”,并接受许多外部刺激。它也是特应性皮炎的常见症状。Dupilumab是第一个被批准用于治疗中重度特应性皮炎(AD)的靶向生物药物。没有关于在AD和唇炎患者中使用dupilumab的真实临床数据。这项回顾性研究比较了dupilumab治疗后患有唇炎的AD患者皮肤病变的改善情况,并评估了唇炎的改善情况。
UNASSIGNED:这是一个回顾性病例系列。我们调查了2020年9月至2022年5月在我们部门接受dupilumab治疗的AD患者,包括唇炎患者。人口统计信息,如年龄,性别,AD或其他特应性病史,并收集皮炎的解剖部位。使用湿疹面积和严重程度指数评分(EASI)评估疾病严重程度,体表面积(BSA),和唇炎的严重程度评估(唇炎症状评分)在基线和16周后。
UNASSIGNED:我们回顾了96例接受dupilumab治疗的AD患者,包括10例唇炎患者(10.4%)。所有患者的皮肤病变均有明显改善,7名患者的嘴唇症状有所改善。在唇炎改善的AD患者中,在第8周时,BSA的EASI平均降低35.0%(34.9%),唇炎症状评分为29.9%.在第16周,与基线评分相比,唇炎症状评分改善为58.1%,EASI为60.8%,BSA为56.2%,分别。
未经批准:dupilumab可有效治疗皮肤和唇炎。唇炎受累的改善比皮肤病变的改善慢。该病例系列证实dupilumab可能是治疗特应性皮炎相关唇受累患者的有价值的方法。
UNASSIGNED: The lip is a unique tissue type that acts as a \"barrier\" to the mouth and receives many external stimuli. It is also a common symptom in atopic dermatitis. Dupilumab was the first targeted biological drug approved for the treatment of moderate-to-severe atopic dermatitis (AD). There is no real-world clinical data on the use of dupilumab in patients with AD and
cheilitis. This retrospective study compared the improvement in skin lesions in AD patients with cheilitis after dupilumab treatment and evaluated the improvement in
cheilitis.
UNASSIGNED: This is a retrospective case series. We investigated patients with AD treated with dupilumab in our department from September 2020 to May 2022, including those with cheilitis. Demographic information such as age, sex, AD or other atopy history, and the anatomical site of dermatitis was collected. Disease severity was assessed using the eczema area and severity index score (EASI), body surface area (BSA), and severity assessment of cheilitis (the
cheilitis symptom score) at baseline and after 16 weeks.
UNASSIGNED: We reviewed 96 patients treated with dupilumab for AD, and including the 10 patients with cheilitis (10.4%). All patients demonstrated significant improvement in skin lesions, and lip symptoms improved in seven patients. Among AD patients with improved cheilitis, the average reduction in EASI was 35.0% for BSA (34.9%) and the
cheilitis symptom score was 29.9% at week 8. At week 16, compared with the baseline score, the improvement in cheilitis symptom scores was 58.1%, EASI was 60.8%, and BSA was 56.2%, respectively.
UNASSIGNED: Effective treatment of both the skin and cheilitis was achieved with dupilumab. The improvement in
cheilitis involvement was slower than that in skin lesions. This case series confirms that dupilumab could be a valuable approach for treating patients with atopic dermatitis-associated lip involvement.